with proteins, nucleic acids, lipids, and metabolites for intercellular communication. EVs have different sizes and have been classified into small EVs (sEVs; < 100 to ~ 200 nm) and medium/large EVs (> 200 nm up to 2000 nm), with the latter known also as microvesicles and, ...
TRF treatment enhanced the sensitivity of cisplatin-induced reduction in the viability of mesothelioma H28 cells via inhibition of PI3K-AKT signaling Nakashima et al. [131] Doxorubicin/Epirubicin γ-Tocotrienol potentiated the apoptotic effect of doxorubicin in hepatocellular carcinoma (HCC) cells Rajendra...
GaraKaren Kelly - 《Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer》 被引量: 0发表: 2017年 Phase II Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemo Naive Patients with Unresectable Malignant Pleural Mesothelioma ...
Financial help for patients. Cancer doctors use video and photos to explain newest, most effective treatements for colorectal, liver and prostate cancers as well as brain, lung, pancreatic, uterine, breast, skin, and other cancers. Alternative and compl
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study Lancet Oncol., 18 (2017), pp. 1386-1396, 10.1016/S1470-2045(17)30621-6 View PDFView articleView in ScopusGoogle Scholar 5...
antibody with cisplatin/pemetrexed in malignant pleural mesothelioma, in which more patients showed transient tumor-specific T cell responses and achieved long-term survival [83]. The combination of carboplatin or cisplatin, pemetrexed/pembrolizumab, was approved by FDA for the first-line treatment of ...
In some cases, CXCR7 modulators are administered to treat cancer, e.g., carcinomas, gliomas, mesotheliomas, melanomas, lymphomas, leukemias (including acute lymphocytic leukemias), adenocarcinomas, breast cancer, ovarian cancer, cervical cancer, glioblastoma, leukemia, lymphoma, prostate cancer, and ...
Given the propensity of serious side effects and limited clinical benefits to date for Chk1i, it may seem counterintuitive that targeting ATR, which acts upstream of Chk1, would have fewer adverse effects on normal tissues. Nonetheless, potent and relatively specific ATRi have been developed and ...
Inhibitor HA14-1 and derivatives BH3Is 2-Methoxy-antimycin A3 (-)-Gossypol TW-37 Apogossypolone and derivatives BI-97CI Chelerythrine YC137 Obatoclax ABT-737/263 S1 Cancer Models Lymphoma, leukemia, myeloma, glioma, ovarian, prostate Leukemia, cervical, glioma Lung, mesothelioma, esophageal ...